This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
JOHNSON DB, NEBHAN CA, MOSLEHI JJ, BALKO JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254-67.Search in Google Scholar
JACOB JB, JACOB MK, PARAJULI P. Review of immune checkpoint inhibitors in immuno-oncology. Adv Pharmacol. 2021;91:111-39.Search in Google Scholar
BAGCHI S, YUAN R, ENGLEMAN EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2021;16:223-49.Search in Google Scholar
IRANZO P, CALLEJO A, ASSAF JD, MOLINA G, LOPEZ DE, GARCIA-ILLESCAS D, et al. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. 2022;9:875974.Search in Google Scholar
CAPPELLO G, MOLEA F, CAMPANELLA D, GALIOTO F, RUSSO F, REGGE D. Gastrointestinal adverse events of immunotherapy. BJR Open. 2021;3(1):20210027.Search in Google Scholar
DOUGAN M, WANG Y, RUBIO-TAPIA A, LIM JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology. 2021;160(4):1384-93.Search in Google Scholar
SCHNEIDER BJ, NAIDOO J, SANTOMASSO BD, LACCHETTI C, ADKINS S, ANADKAT M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology. 2021;39(36):4073-126.Search in Google Scholar
BELLAGUARDA E, HANAUER S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020;115(2):202-10.Search in Google Scholar
BAXI S, YANG A, GENNARELLI RL, KHAN N, WANG Z, BOYCE L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. Bmj. 2018;360:k793.Search in Google Scholar
DE VELASCO G, JE Y, BOSSÉ D, AWAD MM, OTT PA, MOREIRA RB, et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017;5(4):312-8.Search in Google Scholar
WANG PF, CHEN Y, SONG SY, WANG TJ, JI WJ, LI SW, et al. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730.Search in Google Scholar
YAO J, LI M, ZHANG H, GE Y, WEYGANT N, AN G. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. Int Immunopharmacol. 2020;87:106770.Search in Google Scholar
WANG DY, YE F, ZHAO S, JOHNSON DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology. 2017;6(10):e1344805.Search in Google Scholar
WANG Y, ABU-SBEIH H, MAO E, ALI N, ALI FS, QIAO W, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6(1):37.Search in Google Scholar
SINGH H, KIM G, MAHER VE, BEAVER JA, PAI-SCHERF LH, BALASUBRAMANIAM S, et al. FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. Journal of Clinical Oncology. 2016;34(15_suppl):10010-.Search in Google Scholar
KONO M, SHATILA M, XU G, LU Y, MATHEW A, MOHAJIR W, et al. Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis. Cancers (Basel). 2023;15(8).Search in Google Scholar
DUBIN K, CALLAHAN MK, REN B, KHANIN R, VIALE A, LING L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.Search in Google Scholar
CHAPUT N, LEPAGE P, COUTZAC C, SOULARUE E, LE ROUX K, MONOT C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368-79.Search in Google Scholar
MARTHEY L, MATEUS C, MUSSINI C, NACHURY M, NANCEY S, GRANGE F, et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(4):395-401.Search in Google Scholar
GROVER S, DOUGAN M, TYAN K, GIOBBIE-HURDER A, BLUM SM, ISHIZUKA J, et al. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020;126(16):3758-67.Search in Google Scholar
AHMADZADEH M, JOHNSON LA, HEEMSKERK B, WUNDERLICH JR, DUDLEY ME, WHITE DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537-44.Search in Google Scholar
FREEMAN GJ, LONG AJ, IWAI Y, BOURQUE K, CHERNOVA T, NISHIMURA H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-34.Search in Google Scholar
JIANG X, WANG J, DENG X, XIONG F, GE J, XIANG B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Molecular Cancer. 2019;18(1):10.Search in Google Scholar
HAN Y, LIU D, LI L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-42.Search in Google Scholar
ROWSHANRAVAN B, HALLIDAY N, SANSOM DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58-67.Search in Google Scholar
MASTELLER EL, CHUANG E, MULLEN AC, REINER SL, THOMPSON CB. Structural analysis of CTLA-4 function in vivo. J Immunol. 2000;164(10):5319-27.Search in Google Scholar
LENSCHOW DJ, WALUNAS TL, BLUESTONE JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-58.Search in Google Scholar
WING K, ONISHI Y, PRIETO-MARTIN P, YAMAGUCHI T, MIYARA M, FEHERVARI Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271-5.Search in Google Scholar
TAKAHASHI Y, NAGAYA T, IWAYA Y, OKAMURA T, HIRAYAMA A, IWAYA M, et al. CD8(+) Lymphocyte Infiltration Is a Specific Feature of Colitis Induced by Immune Checkpoint Inhibitors. Dig Dis Sci. 2023;68(2):451-9.Search in Google Scholar
TERRIN M, MIGLIORISI G, DAL BUONO A, GABBIADINI R, MASTROROCCO E, QUADARELLA A, et al. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. 2023;24(14):11504.Search in Google Scholar
WESTDORP H, SWEEP MWD, GORRIS MAJ, HOENTJEN F, BOERS-SONDEREN MJ, POST RSVD, et al. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. 2021;12:768957.Search in Google Scholar
BONANNO L, LORENZI M, MASSA D, DE NUZZO M, ANGERILLI V, ZINGONE F, et al. Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting. Oncologist. 2023:oyad238.Search in Google Scholar
HASHASH JG, FRANCIS FF, FARRAYE FA. Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. Gastroenterol Hepatol (N Y). 2021;17(8):358-66.Search in Google Scholar
MENON T, AFZALI A. Immune-Mediated Colitis. Current Treatment Options in Gastroenterology. 2019;17(4):506-23.Search in Google Scholar
SOM A, MANDALIYA R, ALSAADI D, FARSHIDPOUR M, CHARABATY A, MALHOTRA N, et al. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases. 2019;7(4):405-18.Search in Google Scholar
TANG L, WANG J, LIN N, ZHOU Y, HE W, LIU J, et al. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. 2021;12:800879.Search in Google Scholar
HAANEN J, CARBONNEL F, ROBERT C, KERR KM, PETERS S, LARKIN J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv42.Search in Google Scholar
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0: U.S. Department of Health and Human Services. National Institutes of Health National Cancer Institute; 2017.Search in Google Scholar
GEUKES FOPPEN MH, ROZEMAN EA, VAN WILPE S, POSTMA C, SNAEBJORNSSON P, VAN THIENEN JV, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3(1):e000278.Search in Google Scholar
BERMAN D, PARKER SM, SIEGEL J, CHASALOW SD, WEBER J, GALBRAITH S, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.Search in Google Scholar
WANG Y, ABU-SBEIH H, MAO E, ALI N, QIAO W, TRINH VA, et al. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflamm Bowel Dis. 2018;24(8):1695-705.Search in Google Scholar
WRIGHT AP, PIPER MS, BISHU S, STIDHAM RW. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2019;49(12):1474-83.Search in Google Scholar
HUGHES MS, MOLINA GE, CHEN ST, ZHENG H, DESHPANDE V, FADDEN R, et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):292.Search in Google Scholar
CRAMER P, BRESALIER RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Curr Gastroenterol Rep. 2017;19(1):3.Search in Google Scholar
SAMAAN MA, MOSLI MH, SANDBORN WJ, FEAGAN BG, DʼHAENS GR, DUBCENCO E, et al. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014;20(8):1465-71.Search in Google Scholar
CHEN JH, PEZHOUH MK, LAUWERS GY, MASIA R. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. Am J Surg Pathol. 2017;41(5):643-54.Search in Google Scholar
GONZALEZ RS, SALARIA SN, BOHANNON CD, HUBER AR, FEELY MM, SHI C. PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology. 2017;70(4):558-67.Search in Google Scholar
SHIRAVAND Y, KHODADADI F, KASHANI SMA, HOSSEINI-FARD SR, HOSSEINI S, SADEGHIRAD H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044-60.Search in Google Scholar
WOJTUKIEWICZ MZ, REK MM, KARPOWICZ K, GÓRSKA M, POLITYŃSKA B, WOJTUKIEWICZ AM, et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40(3):949-82.Search in Google Scholar
